NOW APPROVED FOR
HEMOPHILIA B and A
More than a pen—
your everyday bleed protectiona
Prophylaxis treatment in a prefilled, subcutaneous pen to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia B or A with or without inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age.
aIt is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding.
Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.
Needles provided separately and may require a prescription in some states.
See the science about how Alhemo® works in the clotting cascade
Everyday bleed protectiona in a pen designed with you in mind
aIt is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding.
- Portable and ready to use: Prefilled, no mixing requiredb,c
- Ultra-thin 32G 4 mm needle, low injection volumed
- Ultra-thin 32G 4 mm needle, low injection volumed
- Safe to use with Factor 8, Factor 9, or all bypassing agents (BPAs)e
- Safety demonstrated in 320 patients, including:
- 66 with hemophilia B
- 133 with hemophilia B or A with inhibitors
Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.
The most frequently reported adverse reactions (incidence ≥ 5%) were injection site reactions, headaches, and urticaria.
320 males with hemophilia A with and without inhibitors and hemophilia B with and without inhibitors received at least one dose of Alhemo as routine prophylaxis. 52 people with inhibitors were previously treated with on-demand therapy and were randomized to receive on-demand treatment with bypassing agents (19 people) or Alhemo® prophylaxis (33 people).
- Power to prevent bleeds:
- 1.7 average and 0 median bleed rate with Alhemo® in hemophilia B or A with inhibitors
- 3.1 average and 1.6 median bleed rate with Alhemo® in hemophilia B
Clinical study of Alhemo® included people ages 12 years and older who had hemophilia B with inhibitors (53 people) and hemophilia A with inhibitors (80 people) who were treated with or are in need of either bypassing agents on demand (at least 24 weeks) or Alhemo® once-daily prophylaxis (at least 32 weeks). 86% annual bleed rate (ABR) reduction with Alhemo® (33 people) compared with on-demand bypassing agents (19 people). The mean ABR was 1.7 for people treated with Alhemo® and 11.8 for people treated with on-demand BPAs. The median ABR was 0 for patients on Alhemo® and 9.8 for patients on no prophylaxis.
Clinical study of Alhemo® included 156 people aged 12 years and older who had hemophilia A or B without inhibitors. Alhemo® was assessed in a group of people who had previously received on-demand factor replacement, including 12 people with hemophilia B who were treated with no prophylaxis (on-demand Factor 9 replacement) and 24 people with hemophilia B who received Alhemo® prophylaxis for at least 32 weeks.
The mean ABR was 3.1 for people treated with Alhemo® and 14.8 for people treated with on-demand Factor 9. The median ABR was 1.6 for people on Alhemo® and 14.9 for people treated with on-demand Factor 9.
For people with hemophilia A (27 people), the average ABR was 19.3 for those using on-demand Factor 8 and 2.7 for those using Alhemo® prophylaxis. This corresponded to a reduction of 86%.
Clinical study of Alhemo® included 156 people aged 12 years and older who had hemophilia A or B without inhibitors. Alhemo® was assessed in a group of people who had previously received on-demand factor replacement, including 12 people with hemophilia B who were treated with no prophylaxis (on-demand Factor 9 replacement) and 24 people with hemophilia B who received Alhemo® prophylaxis for at least 32 weeks.
The mean ABR was 3.1 for people treated with Alhemo® and 14.8 for people treated with on-demand Factor 9. The median ABR was 1.6 for people on Alhemo® and 14.9 for people treated with on-demand Factor 9.
For people with hemophilia A (27 people), the average ABR was 19.3 for those using on-demand Factor 8 and 2.7 for those using Alhemo® prophylaxis. This corresponded to a reduction of 86%.
bStore in refrigerator before first use. After first use, Alhemo® can be stored at room temperature below 86 ℉ (30 ℃) or in a refrigerator at 36 ℉ to 46 ℉ (2 ℃ to 8 ℃) for up to 4 weeks.
cRead the Instructions for Use for information about how to prepare and inject Alhemo®, and how to properly throw away used pens and needles. Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.
dFor a person who weighs 70 kg (154 lb) on a daily dose of 0.2 mg/kg and using the (gold label) 150 mg/1.5 mL pen, the volume to inject is 0.14 mL per dose.
eCarefully follow your healthcare provider’s instructions regarding when to use on-demand Factor 8, Factor 9, or BPAs, and the recommended dose and schedule for breakthrough bleeds.
ABR=annualized bleeding rate.
Alhemo® is a prefilled injection pen for people 12 years and older living with hemophilia B or A with or without inhibitors
Subcutaneous administration (no need for vein access)
No IV infusions
No mixing
No vials
No refrigeration requiredf
(up to 4 weeks after first use)
fStore in refrigerator before first use. After first use, Alhemo® can be stored at room temperature below 86 ℉ (30 ℃) or in a refrigerator at 36 ℉ to 46 ℉ (2 ℃ to 8 ℃) for up to 4 weeks.
Please see Prescribing Information for full storage information.
Needles provided separately and may require a prescription in some states; a new needle is required for each injection.
Life with hemophilia with inhibitors, in their words
Meet members of the community and hear how they navigate life, care, and advocacy.
Jericho lives with hemophilia A with inhibitors and uses Alhemo®. Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.
See the science behind Alhemo®
Alhemo® works by blocking a protein called TFPI, which naturally prevents clotting. By blocking TFPI, Alhemo® helps your blood clot when you’re missing factors 8 or 9 with or without inhibitors.
Powerful bleed protection
Proven to prevent bleeds. Learn more about how Alhemo® works to reduce bleeds.
Subcutaneous administration with a prefilled pen
Administration designed to fit your lifestyle.
Contact a Novo Nordisk Rare Blood Community Liaison (RBCL)
Life with a bleeding disorder can come with challenges—and questions. That’s why Novo Nordisk offers more than treatment. Our Rare Blood Community Liaisons (RBCLs) provide one-on-one support, including:
- Information about Alhemo®
- Education on the condition and daily living
- Local event updates
- Tools to help manage your bleeding disorder
Brittany (left) and Stacey (right) are Novo Nordisk RBCLs.
The latest Alhemo® news
Want to learn more about Alhemo®? Get important email updates, information about patient support programs, and more.
